ClinicalTrials.gg
RecruitingNCT07482657Updated Jul 20, 2026

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

A Phase 2 interventional study of zelicapavir and Placebo in RSV Infection, RSV and Respiratory Syncytial Virus (RSV), sponsored by Enanta Pharmaceuticals, Inc. Recruiting at 8 sites in Thailand. Open to participants aged 28 Days to 36 Months. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
28 Days to 36 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.

Planned enrollment
3rd of 10
150 · median 81
Started
2026
the only one that year
Phase 2
4 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
10 of 10
Enanta Pharmaceuticals, Inc

Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one is the 3rd largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 2, and was the 10th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country.

By country, each count listing its studies:

About EDP-938

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 28 Days to 36 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.

03

Conditions studied

  • RSV Infection
  • RSV
  • Respiratory Syncytial Virus (RSV)

Keywords

  • RSV
  • children
  • Respiratory Syncytial Virus
  • Pediatric study
04

Who can participate

Ages eligible
28 Days to 36 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with RSV infection using an approved diagnostic assay, without known and/or documented coinfection with SARS-CoV-2 or influenza
  • Participant has signs of RSV infection with onset ≤3 days (72 hours) at the time of randomization
  • In the Investigator's opinion, the participant's caregiver understands and is able to comply with protocol requirements, instructions, and restrictions, and the participant is likely to complete the study as planned. The caregiver(s) should be of legal age.

Exclusion criteria

Exclusion Criteria:

  • Participant has any condition that in the opinion of the Investigator would interfere with the evaluation of the study drug or participant safety.
  • Participant has underlying immune deficiency. Participants with immunoglobulin A deficiency are not excluded.
  • Participant has had major surgery within 6 weeks prior to randomization or has major surgery planned during the course of the study.
  • Participant is currently taking either chronically or has taken within 7 days prior to randomization, or is anticipated to receive during the course of the study, systemic medications that are known to cause other than for >5 days.
  • Participant has received an agent within the last 30 days or 5 half-lives of the investigational agent, whichever is longer.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    zelicapavir

    zelicapavir, oral suspension, once daily for 7 days

    Drug: zelicapavir

  • Placebo comparator
    Placebo

    Matching placebo, orally, once daily for 7 days

    Drug: Placebo

Interventions

  • Oral suspension

  • DrugPlacebo

    Placebo oral suspension to match zelicapavir

06

What researchers measure

Primary outcomes

  1. Time to complete resolution of clinical signs of RSV as measured by RESOLVE-P

    Time frame: Day 1 through Day 14

Secondary outcomes

  1. Time to sustained resolution of clinical signs of RSV as measured by RESOLVE-P

    Time frame: Day 1 through Day 14

  2. Change in severity of clinical signs of RSV from Baseline to D7 as measured by RESOLVE-P

    Time frame: Day 1 through Day 7

  3. Proportion of participants with Lower Respiratory Tract Infection (LRTI)

    Time frame: D1 through D14

  4. Change in severity of RSV from Baseline to D7 and D14

    Time frame: Baseline to D7 and D14

  5. Proportion of outpatient participants who were hospitalized due to RSV or other causes during the study period

    Time frame: Day 1 through Day 35

  6. Change in RSV viral load as measured by RT-qPCR

    Time frame: Baseline to D7

  7. Proportion of participants with viral load Target Not Detected (TND)

    Time frame: Day 4, Day 7 and Day 14

  8. Time to viral load TND

    Time frame: Day 1 through Day 14

  9. Plasma PK Concentrations of zelicapavir

    Time frame: Up to Day 7

  10. Safety as measured by frequency of adverse events (AEs)

    Time frame: Up to Day 35

07

Study locations

8 of 8 sites recruiting
  • Center of Excellence for Pediatric Infectious Diseases and Vaccines Faculty of Medicine, Chulalongkorn University (CE-PID)
    Bangkok, 10330, Thailand
    Recruiting
    • Napaporn Chantasrisawad · Contactnapaporn.cha@chula.ac.th · +66 2256 4930
    • Napaporn Chantasrisawad, MD · Principal investigator
  • Nakornping Hospital
    Chiang Mai, 50180, Thailand
    Recruiting
    • Rujirek Kamolrattana · Contactrujirek71@gmail.com · +66 5399 9000
    • Rujirek Kamolrattana, MD · Principal investigator
  • Maharaj Nakorn Chiang Mai Hospital
    Chiang Mai, 50200, Thailand
    Recruiting
    • Tavitiya Sudjaritruk · Contacttavitiya.s@cmu.ac.th · +66 05393 6150
    • Tavitiya Sudjaritruk, MD · Principal investigator
  • Chiangrai Prachanukroh Hospital
    Chiang Rai, 57000, Thailand
    Recruiting
  • Khon Kaen Hospital
    Khon Kaen, 40000, Thailand
    Recruiting
    • Ussanee Srirompotong · Contactu.srirompotong@gmail.com · +66 4300 9900
    • Ussanee Srirompotong, MD · Principal investigator
  • Lampang Hospital
    Lampang, 52000, Thailand
    Recruiting
    • Pakawadi Vuttipittayamongkol · ContactPakawadi@hotmail.com · +66 5423 7400
    • Pakawadi Vuttipittayamongkol, MD · Principal investigator
  • Lamphun Hospital
    Lamphun, 51000, Thailand
    Recruiting
  • Maha Sarakham Hospital
    Maha Sarakham, 44000, Thailand
    Recruiting
    • Supawan Papakhee · Contactsupawan.pa@chula.ac.th · +66 4372 3355
    • Supawan Papakhee, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 5 months is below that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 19, 2026
StartActual
Jul 9, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07482657
Collaborators
PENTA Foundation, AMS-PHPT Research Collaboration, Chiang Mai University
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Jul 9, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 20, 2026

Study contacts

Enanta Pharmaceuticals, Inc
Contact
charris@enanta.com
617 607-0800
Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-938

Start the discussion